Nektar Therapeutics (NASDAQ:NKTR) has earned an average rating of “Buy” from the eight brokerages that are presently covering the firm. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $21.00.

Several research firms recently weighed in on NKTR. Zacks Investment Research lowered shares of Nektar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 1st. Brean Capital restated a “buy” rating and set a $18.00 target price on shares of Nektar Therapeutics in a report on Friday, August 5th. Piper Jaffray Cos. restated an “overweight” rating and set a $21.00 target price (up previously from $17.00) on shares of Nektar Therapeutics in a report on Friday, August 5th. Jefferies Group restated a “buy” rating on shares of Nektar Therapeutics in a report on Thursday, September 8th. Finally, Aegis began coverage on shares of Nektar Therapeutics in a report on Tuesday, November 8th. They set a “buy” rating and a $21.00 target price on the stock.

Nektar Therapeutics (NASDAQ:NKTR) traded down 3.11% on Tuesday, reaching $13.08. The company had a trading volume of 348,187 shares. The stock’s market capitalization is $2.00 billion. Nektar Therapeutics has a 52-week low of $10.52 and a 52-week high of $19.98. The stock has a 50 day moving average price of $14.25 and a 200 day moving average price of $15.70.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.04. The company had revenue of $36.30 million for the quarter, compared to analyst estimates of $32.42 million. Nektar Therapeutics had a negative net margin of 98.87% and a negative return on equity of 8,769.15%. Nektar Therapeutics’s revenue for the quarter was down 39.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.06) EPS. Analysts expect that Nektar Therapeutics will post ($1.07) EPS for the current year.

In related news, Director Robert Chess sold 12,000 shares of Nektar Therapeutics stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $19.21, for a total transaction of $230,520.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Howard W. Robin sold 87,500 shares of Nektar Therapeutics stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $17.83, for a total transaction of $1,560,125.00. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Westfield Capital Management Co. LP bought a new stake in Nektar Therapeutics during the second quarter valued at $17,247,000. BlackRock Fund Advisors increased its stake in Nektar Therapeutics by 7.3% in the third quarter. BlackRock Fund Advisors now owns 10,970,974 shares of the biopharmaceutical company’s stock valued at $188,481,000 after buying an additional 749,496 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Nektar Therapeutics by 97.8% in the third quarter. Price T Rowe Associates Inc. MD now owns 1,156,400 shares of the biopharmaceutical company’s stock valued at $19,867,000 after buying an additional 571,900 shares during the last quarter. RA Capital Management LLC increased its stake in Nektar Therapeutics by 13.6% in the third quarter. RA Capital Management LLC now owns 3,664,154 shares of the biopharmaceutical company’s stock valued at $62,950,000 after buying an additional 439,300 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Nektar Therapeutics by 2.7% in the second quarter. Vanguard Group Inc. now owns 11,650,468 shares of the biopharmaceutical company’s stock valued at $165,787,000 after buying an additional 301,245 shares during the last quarter. 86.69% of the stock is currently owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

5 Day Chart for NASDAQ:NKTR

Receive News & Stock Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related stocks with our FREE daily email newsletter.